These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 20706038

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multiple myeloma: predictive value of Tc-99m MIBI scintigraphy and MRI in its diagnosis and therapy.
    Myslivecek M, Nekula J, Bacovsky J, Scudla V, Koranda P, Kaminek M.
    Nucl Med Rev Cent East Eur; 2008; 11(1):12-6. PubMed ID: 19173182
    [Abstract] [Full Text] [Related]

  • 3. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease.
    Balleari E, Villa G, Garrè S, Ghirlanda P, Agnese G, Carletto M, Clavio M, Ferrando F, Gobbi M, Mariani G, Ghio R.
    Haematologica; 2001 Jan; 86(1):78-84. PubMed ID: 11146575
    [Abstract] [Full Text] [Related]

  • 4. Scintigraphy using (99m)Tc-MIBI (sestamibi), a sensitive parameter of activity of multiple myeloma.
    Bacovsky J, Scudla V, Myslivecek M, Nekula J, Vytrasová M.
    Neoplasma; 2005 Jan; 52(4):302-6. PubMed ID: 16059646
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up.
    Pace L, Catalano L, Del Vecchio S, Di Gennaro F, De Renzo A, Sica G, Califano C, Tedesco N, Borrelli G, Rotoli B, Salvatore M.
    Eur J Nucl Med; 2001 Mar; 28(3):304-12. PubMed ID: 11315597
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. BaselinTc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance.
    Martín MG, Romero Colás MS, Dourdil Sahún MV, Olave P, Alba PR, Banzo JB.
    Haematologica; 2005 Aug; 90(8):1141-3. PubMed ID: 16079119
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic value of Tc-99m-MIBI performed during middle course of preoperative chemotherapy in patients with malignant bone and soft-tissue tumors.
    Wakabayashi H, Taki J, Inaki A, Sumiya H, Zen Y, Tsuchiya H, Kinuya S.
    Clin Nucl Med; 2012 Jan; 37(1):1-8. PubMed ID: 22157020
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
    Ak I, Aslan V, Vardareli E, Gülbaş Z.
    Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
    [Abstract] [Full Text] [Related]

  • 20. Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake.
    Nandurkar D, Kalff V, Turlakow A, Spencer A, Bailey MJ, Kelly MJ.
    Eur J Haematol; 2006 Feb; 76(2):141-6. PubMed ID: 16405435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.